This excerpt taken from the AUXL 8-K filed Dec 18, 2008.
Development, Commercialization and Supply Agreement with Pfizer, Inc.
On December 17, 2008, Auxilium Pharmaceuticals, Inc. (Auxilium), Auxilium International Holdings, Inc., a wholly owned subsidiary of Auxilium, and Pfizer Inc. (Pfizer) (collectively, the Parties, and each individually, a Party) entered into a Development, Commercialization and Supply Agreement (the Agreement). Under the Agreement, Pfizer was granted the right to develop and commercialize Auxiliums pharmaceutical product XIAFLEXTM (clostridial collagenase for injection) (the Product) for the treatment of Peyronies disease and Dupuytrens contracture (the Field) in the 27 member countries of the European Union (as it exists as of the date hereof), Albania, Armenia, Azerbaijan, Belarus, Bosnia & Herzegovina, Croatia, Georgia, Kazakhstan, Kirghiz Republic, Macedonia, Moldova, Montenegro, Serbia, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway (the Territory).
A summary of certain terms of the Agreement is set forth below.
Upfront, Milestone and Commercialization Payments:
Term of the Agreement:
Manufacturing rights/supply obligations:
Future indications in the Territory:
Sharing of development/regulatory/commercialization costs:
Right to terminate agreement/license and effect of termination:
The foregoing is a summary description of certain terms of the Agreement and, by its nature, is incomplete. It is qualified in its entirety by the text of the Agreement, attached as Exhibit 10.1 to this Current Report on Form 8-K. All readers are encouraged to read the entire text of the Agreement. Certain terms of the Agreement have been omitted from this Current Report on Form 8-K and the version of the Agreement attached as Exhibit 10.1 hereto pursuant to a Confidential Treatment Request that Auxilium filed with the Securities and Exchange Commission at the time of the filing this Current Report on Form 8-K.